Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study
Background. Netakimab has shown high efficacy in controlled clinical trials in the treatment of patients with ankylosing spondylitis (AS). This article presents results of an observational study of netakimab using in routine clinical practice.Methods. Patients were recruited for the study from Augus...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2024-01-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3472 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240224516800512 |
|---|---|
| author | Sh. Erdes V. I. Mazurov I. Z. Gaydukova O. N. Anoshenkova I. B. Vinogradova Yu. Yu. Grabovetskaya S. Yu. Davidian O. E. Epifanova N. A. Kiryukhina L. V. Masneva I. V. Menshikova O. N. Mironenko N. E. Nikulenkova T. V. Povarova A. N. Polyatika R. R. Samigullina A. E. Sizikov I. N. Totrov I. F. Umnova J. V. Usacheva A. L. Chudinov |
| author_facet | Sh. Erdes V. I. Mazurov I. Z. Gaydukova O. N. Anoshenkova I. B. Vinogradova Yu. Yu. Grabovetskaya S. Yu. Davidian O. E. Epifanova N. A. Kiryukhina L. V. Masneva I. V. Menshikova O. N. Mironenko N. E. Nikulenkova T. V. Povarova A. N. Polyatika R. R. Samigullina A. E. Sizikov I. N. Totrov I. F. Umnova J. V. Usacheva A. L. Chudinov |
| author_sort | Sh. Erdes |
| collection | DOAJ |
| description | Background. Netakimab has shown high efficacy in controlled clinical trials in the treatment of patients with ankylosing spondylitis (AS). This article presents results of an observational study of netakimab using in routine clinical practice.Methods. Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included patients who were prescribed netakimab therapy before enrollment, so clinical and medical history data for the first visit were entered retrospectively, and following visits at weeks 12, 24 and 52 of therapy were collected within the study. Drug survival rate has been calculated according to Kaplan – Meier analysis.Results. The study included 137 patients (93 men and 14 women) with AS. The average age of patients was 42.3 (±11.9) years, 34.3% of patients had previously received therapy with genetically engineered biologic drugs, mainly tumor necrosis factor inhibitors. At the end of the analyzed period (52 weeks of therapy), 90.4% [95% CI: 85.4–95.7] of patients continued treatment with netakimab. The BASDAI and ASDAS-CRP showed statistically significant decreases in scores from baseline at all time points. Netakimab was well tolerated by patients; adverse effects (AEs), related to therapy according to the investigator’s opinion, were reported in 7 (5.1%) patients. 2 patients stopped taking netakimab due to AEs: terminal ileitis and chronic colitis.Conclusions. In real-world clinical practice, netakimab demonstrated high retention rates, a favorable safety profile, and sustained efficacy throughout the first year of therapy. |
| format | Article |
| id | doaj-art-7e5bc44473f34733b5ff6008d493e861 |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2024-01-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-7e5bc44473f34733b5ff6008d493e8612025-08-20T04:00:40ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922024-01-0161670071010.47360/1995-4484-2023-700-7102948Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety studySh. Erdes0V. I. Mazurov1I. Z. Gaydukova2O. N. Anoshenkova3I. B. Vinogradova4Yu. Yu. Grabovetskaya5S. Yu. Davidian6O. E. Epifanova7N. A. Kiryukhina8L. V. Masneva9I. V. Menshikova10O. N. Mironenko11N. E. Nikulenkova12T. V. Povarova13A. N. Polyatika14R. R. Samigullina15A. E. Sizikov16I. N. Totrov17I. F. Umnova18J. V. Usacheva19A. L. Chudinov20V.A. Nasonova Research Institute of RheumatologyNorth-Western State Medical University named after I.I. MechnikovNorth-Western State Medical University named after I.I. MechnikovMedical Center “Maksimum zdorovya”Ulyanovsk Regional Clinical HospitalKaliningrad Regional Clinical HospitalPirogov National Medical and Surgical CenterMedical Center “RhevmaMed” LLCPirogov National Medical and Surgical CenterBelgorod Regional Clinical HospitalI.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)BIOCAD JSCVladimir Regional Clinical HospitalRailway Clinical Hospital at the Station Saratov II, Russian Railways Ltd.Artrologiya LLCNorth-Western State Medical University named after I.I. MechnikovResearch Institute of Fundamental and Clinical ImmunologyNorth-Ossetian State Medical AcademyOmsk Regional Clinical HospitalBIOCAD JSCNorth-Western State Medical University named after I.I. MechnikovBackground. Netakimab has shown high efficacy in controlled clinical trials in the treatment of patients with ankylosing spondylitis (AS). This article presents results of an observational study of netakimab using in routine clinical practice.Methods. Patients were recruited for the study from August 2020 to December 2021 at 23 centers in the Russian Federation. The study included patients who were prescribed netakimab therapy before enrollment, so clinical and medical history data for the first visit were entered retrospectively, and following visits at weeks 12, 24 and 52 of therapy were collected within the study. Drug survival rate has been calculated according to Kaplan – Meier analysis.Results. The study included 137 patients (93 men and 14 women) with AS. The average age of patients was 42.3 (±11.9) years, 34.3% of patients had previously received therapy with genetically engineered biologic drugs, mainly tumor necrosis factor inhibitors. At the end of the analyzed period (52 weeks of therapy), 90.4% [95% CI: 85.4–95.7] of patients continued treatment with netakimab. The BASDAI and ASDAS-CRP showed statistically significant decreases in scores from baseline at all time points. Netakimab was well tolerated by patients; adverse effects (AEs), related to therapy according to the investigator’s opinion, were reported in 7 (5.1%) patients. 2 patients stopped taking netakimab due to AEs: terminal ileitis and chronic colitis.Conclusions. In real-world clinical practice, netakimab demonstrated high retention rates, a favorable safety profile, and sustained efficacy throughout the first year of therapy.https://rsp.mediar-press.net/rsp/article/view/3472netakimabdrug retention rateankylosing spondylitis |
| spellingShingle | Sh. Erdes V. I. Mazurov I. Z. Gaydukova O. N. Anoshenkova I. B. Vinogradova Yu. Yu. Grabovetskaya S. Yu. Davidian O. E. Epifanova N. A. Kiryukhina L. V. Masneva I. V. Menshikova O. N. Mironenko N. E. Nikulenkova T. V. Povarova A. N. Polyatika R. R. Samigullina A. E. Sizikov I. N. Totrov I. F. Umnova J. V. Usacheva A. L. Chudinov Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study Научно-практическая ревматология netakimab drug retention rate ankylosing spondylitis |
| title | Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study |
| title_full | Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study |
| title_fullStr | Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study |
| title_full_unstemmed | Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study |
| title_short | Real-world retention rate, effectiveness, and safety of netakimab in the treatment of patients with ankylosing spondylitis: First year results of the LIBRA post-registration safety study |
| title_sort | real world retention rate effectiveness and safety of netakimab in the treatment of patients with ankylosing spondylitis first year results of the libra post registration safety study |
| topic | netakimab drug retention rate ankylosing spondylitis |
| url | https://rsp.mediar-press.net/rsp/article/view/3472 |
| work_keys_str_mv | AT sherdes realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT vimazurov realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT izgaydukova realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT onanoshenkova realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT ibvinogradova realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT yuyugrabovetskaya realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT syudavidian realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT oeepifanova realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT nakiryukhina realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT lvmasneva realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT ivmenshikova realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT onmironenko realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT nenikulenkova realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT tvpovarova realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT anpolyatika realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT rrsamigullina realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT aesizikov realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT intotrov realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT ifumnova realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT jvusacheva realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy AT alchudinov realworldretentionrateeffectivenessandsafetyofnetakimabinthetreatmentofpatientswithankylosingspondylitisfirstyearresultsofthelibrapostregistrationsafetystudy |